Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  The Journal of Neuropsychiatry and Clinical Neurosciences

• Publication date

  2000-05-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1176/JNP.12.2.209PMID 11001599
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intravenous nicotine in Alzheimer's disease: a pilot study

  2004cited by this paper
• Analyzing functional brain images in a probabilistic atlas: a validation of subvolume thresholding.

  2000cited by this paper
• The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease.

  1999cited by this paper
• Automated image registration: II. Intersubject validation of linear and nonlinear models.

  1998cited by this paper
• A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

  1998cited by this paper
• Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease

  1998cited by this paper
• The limbic system: an anatomic, phylogenetic, and clinical perspective.

  1997cited by this paper
• Neuropsychiatric aspects of Alzheimer's disease

  1996cited by this paper
• Effect of Tacrine on Behavioral Symptoms in Alzheimer's Disease: An Open-Label Study

  1996cited by this paper
• Abnormal brain glucose metabolism in the delusional misidentification syndromes: a positron emission tomography study in Alzheimer disease.

  1995cited by this paper
• The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease.

  1995cited by this paper
• A SPECT study of delusions in Alzheimer's disease

  1994cited by this paper
• The Neuropsychiatric Inventory

  1994cited by this paper
• Physostigmine ameliorates the delusions of Alzheimer's disease.

  1993cited by this paper
• The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease.

  1991cited by this paper
• Statistical Data Analysis in the Computer Age

  1991cited by this paper
• Cerebral Pharmacodynamics of Physostigmine in Alzheimer's Disease Investigated Using Single-Photon Computerised Tomography

  1991cited by this paper
• Anterior cerebral artery territory infarction in the Lausanne Stroke Registry. Clinical and etiologic patterns.

  1990cited by this paper
• Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations.

  1988cited by this paper
• Intraventricular bethanechol in Alzheimer's disease

  1988cited by this paper
• Induction of depression with oxotremorine in patients with Alzheimer's disease.

  1987cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Reversible dementia. Illustrative cases, definition, and review.

  1980cited by this paper
• The Quality of Survival after Rupture of an Anterior Cerebral Aneurysm

  1968cited by this paper
• Three Cases of Frontal Meningiomas Presenting Psychiatrically

  1968cited by this paper

• The increased effective connectivity from left middle occipital gyrus to right medial septum/diagonal bands in AD patients after donepezil intervention

  2024cites this paper
• Predicting the efficacy of donepezil intervention in Alzheimer’s disease patients using regional homogeneity in the inferior orbitofrontal cortex

  2024cites this paper
• Prospective classification of Alzheimer's disease conversion from mild cognitive impairment

  2023cites this paper
• Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review

  2022cites this paper
• Acute response to cholinergic challenge predicts long‐term response to galantamine treatment in patients with Alzheimer's disease

  2021cites this paper
• A New Way Forward: How Brain SPECT Imaging Can Improve Outcomes and Transform Mental Health Care Into Brain Health Care

  2021cites this paper
• Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns

  2021cites this paper
• The Neuropsychiatric Inventory: Development and Applications

  2020cites this paper
• Effect of desalted Salicornia europaea L. ethanol extract (PM-EE) on the subjects complaining memory dysfunction without dementia: a 12 week, randomized, double-blind, placebo-controlled clinical trial

  2020cites this paper
• A Narrative Review on Clinical Applications of fNIRS

  2020cites this paper
• Early prediction of donepezil cognitive response in Alzheimer’s disease by brain perfusion single photon emission tomography

  2019cites this paper
• Treatment of Late-Life Psychosis

  2018cites this paper
• Brain Scanning and Therapeutics

  2018cites this paper
• Predicting the neural effect of switching from donepezil to galantamine based on single‐photon emission computed tomography findings in patients with Alzheimer's disease

  2016cites this paper
• Five-Year Longitudinal Brain Volume Change in Healthy Elders at Genetic Risk for Alzheimer’s Disease

  2016cites this paper
• Early Development of Symptomatic Drugs in AD: A Systematic Review of the Use of Biomarkers.

  2016cites this paper
• Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies

  2016cites this paper
• Neuroimaging correlates of neuropsychiatric symptoms in Alzheimer's disease: a review of 20 years of research

  2016cites this paper
• Single Photon Emission Computerized Tomography and Neuropsychological Tests That Predict a Good Response to Donepezil Therapy for Alzheimer's Disease

  2015cites this paper
• Effects of donepezil dose escalation in Parkinson's patients with dementia receiving long‐term donepezil treatment: an exploratory study

  2014cites this paper
• A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia.

  2014cites this paper
• Anosognosia and Anosodiaphoria in Mild Cognitive Impairment and Alzheimer's Disease

  2014cites this paper
• Brain perfusion single photon emission computed tomography in major psychiatric disorders: From basics to clinical practice

  2014cites this paper
• Cognitive and neuropsychiatric disorders among multiple sclerosis patients from Latin America: Results of the RELACCEM study.

  2014cites this paper
• The role of near-infrared spectroscopy in Alzheimer's disease

  2013cites this paper
• Influence of Personality on the Relationship Between Gray Matter Volume and Neuropsychiatric Symptoms in Multiple Sclerosis

  2013cites this paper
• Brain SPECT Imaging in Complex Psychiatric Cases: An Evidence-Based, Underutilized Tool

  2011cites this paper
• Emotion and Behavior in Alzheimer's Disease and Other Dementias

  2011cites this paper
• Management of behavioral problems in Alzheimer's disease

  2010cites this paper
• Frontotemporal dementia: therapeutic interventions.

  2009cites this paper
• The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES)

  2009cites this paper
• Responders to ChEI treatment of Alzheimer's disease show restitution of normal regional cortical activation.

  2009cites this paper
• Carotid Intima-Media Thickness as a Predictor of Response to Cholinesterase Inhibitors in Alzheimer’s Disease

  2009cites this paper
• Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease.

  2008cites this paper
• SPECT-Identified Neuroanatomical Predictor of the Cognitive Effects of Donepezil Treatment in Patients with Alzheimer’s Disease

  2008cites this paper
• Molecular Imaging and Magnetic Resonance Imaging in Early Diagnosis of Alzheimer's Disease

  2008cites this paper
• Predicting Positive and Negative Treatment Responses to Stimulants with Brain SPECT Imaging

  2008cites this paper
• Traitement médical des manifestations psychiatriques et comportementales de la maladie d'Alzheimer

  2008cites this paper
• Reduced prefrontal oxygenation in Alzheimer disease during verbal fluency tasks.

  2008cites this paper
• Neuropsychiatric evaluation in dementia.

  2008cites this paper
• Role of Neuroimaging in Alzheimer's Disease, with Emphasis on Brain Perfusion SPECT*

  2007cites this paper
• Treatment Strategies for the Behavioral Symptoms of Alzheimer's Disease: Focus on Early Pharmacologic Intervention

  2007cites this paper
• Chapter 16 Behavioral Syndromes and Their Treatment

  2007cites this paper
• A wavelet-based statistical analysis of fMRI data

  2007cites this paper
• Cognitive Predictors of Donepezil Therapy Response in Alzheimer Disease

  2007cites this paper
• Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement.

  2007cites this paper
• Symptomatic treatment of Alzheimer's disease: identification of biomarkers to aid translation from bench to bedside.

  2007cites this paper
• Imaging treatment effects in Alzheimer's disease.

  2007cites this paper
• The effect of drugs for Alzheimer disease assessed by means of neuroradiological techniques.

  2006cites this paper
• Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment

  2006cites this paper
• Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies

  2006cites this paper
• The neurobiology of neuropsychiatric syndromes in dementia

  2006cites this paper
• Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer’s disease

  2006influential citation
• Behavioural and neuropsychological correlates of frontal lobe features in dementia

  2006cites this paper
• Functional neuroimaging in Alzheimer's disease

  2006cites this paper
• Verbal repetition in patients with Alzheimer's disease who receive donepezil

  2006cites this paper
• Leczenie choroby Alzheimera: czy istnieją możliwości przewidywania klinicznej odpowiedzi na inhibitory cholinesterazy?

  2006cites this paper
• Cerebral perfusion patterns associated with the clinical response to donepezil therapy in Alzheimer's disease patients

  2006cites this paper
• Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s disease

  2005cites this paper
• Genetics of brain structure and intelligence.

  2005cites this paper
• Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease.

  2005cites this paper
• Do Vascular Lesions and Related Risk Factors Influence Responsiveness to Donepezil Chloride in Patients with Alzheimer’s Disease?

  2005cites this paper
• [Changing the anticholinesterase in Alzheimer's disease].

  2005cites this paper
• Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.

  2005cites this paper
• A Review of Rating Scales for Measuring Behavior Change Due to Frontal Systems Damage

  2005cites this paper
• Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients

  2004cites this paper
• Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease.

  2004influential citation
• Cerebral Perfusional Effects of Cholinesterase Inhibitors in Alzheimer Disease

  2004cites this paper
• Managing agitation and difficult behavior in dementia.

  2004cites this paper
• Psychiatric issues in non-Alzheimer dementias

  2004cites this paper
• Behavioral Problems in Dementia: A Factor Analysis of the Neuropsychiatric Inventory

  2003cites this paper
• Executive dysfunction and apathy predict functional impairment in Alzheimer disease.

  2003cites this paper
• Regional Cerebral Blood Flow Patterns and Response to Donepezil Treatment in Patients with Alzheimer’s Disease

  2003cites this paper
• Cholinesterase Inhibitor Therapies and Neuropsychiatric Manifestations of Alzheimer’s Disease

  2003cites this paper
• [Characteristics of MRI features in Alzheimer's disease patients predicting response to donepezil treatment].

  2003cites this paper
• Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.

  2003cites this paper
• Change of Regional Cerebral Blood Flow in Alzheimer`s Disease Patients treated with Cholinesterase Inhibitors

  2003cites this paper
• [Treatment of psychiatric and behavioural symptoms in Alzheimer's disease].

  2003cites this paper
• An Observational Clinical Study of the Efficacy and Tolerability of Donepezil in the Treatment of Alzheimer’s Disease

  2003cites this paper
• Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

  2003cites this paper
• La désinhibition dans la maladie d'Alzheimer : évaluation, prévalence et traitement

  2002cites this paper
• Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors.

  2002cites this paper
• A short review of cognitive and functional neuroimaging studies of cholinergic drugs: implications for therapeutic potentials

  2002cites this paper
• Brain perfusional spect in early Alzheimer's disease related to efficacy of donepezil

  2002cites this paper
• Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration

  2002cites this paper
• Annotation: the role of prefrontal deficits, low autonomic arousal, and early health factors in the development of antisocial and aggressive behavior in children.

  2002cites this paper
• Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: bridging the gap between evidence and practice

  2001cites this paper
• Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease.

  2001cites this paper
• Cholinesterase inhibitors for behavioral disturbance in dementia

  2001cites this paper
• Neuropsychiatric assessment of Alzheimer’s disease and related dementias

  2001cites this paper
• Cerebral blood flow and metabolic abnormalities in Alzheimer’s disease

  2001cites this paper
• The cholinergic deficit in Alzheimer's disease: impact on cognition, behaviour and function.

  2000cites this paper
• Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents

  2000cites this paper